Laser-Assisted Delivery of Topical Rapamycin: mTOR Inhibition for Birt-Hogg-Dube Syndrome

Dermatol Surg. 2019 Dec;45(12):1713-1715. doi: 10.1097/DSS.0000000000001778.

Authors

David Kim¹, Ashley Wysong, Joyce M Teng, Zakia Rahman

Affiliation

¹ Department of Dermatology, Keck School of Medicine of USC, Los Angeles, California Department of Dermatology, University of Nebraska Medical Center, Omaha, Nebraska Department of Dermatology, Stanford University School of Medicine, Redwood City, California.

PMID: 30640787
DOI: 10.1097/DSS.0000000000001778

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Administration, Cutaneous
Aged
Biopsy
Birt-Hogg-Dube Syndrome / diagnosis
Birt-Hogg-Dube Syndrome / drug therapy*
Birt-Hogg-Dube Syndrome / genetics
Combined Modality Therapy / instrumentation
Combined Modality Therapy / methods
Humans
Lasers*
Low-Level Light Therapy / instrumentation
Low-Level Light Therapy / methods*
Male
Ointments
Proto-Oncogene Proteins / genetics
Proto-Oncogene Proteins / metabolism
Signal Transduction / drug effects
Signal Transduction / genetics
Sirolimus / administration & dosage*
Skin / drug effects
Skin / pathology
Skin / radiation effects
TOR Serine-Threonine Kinases / antagonists & inhibitors
TOR Serine-Threonine Kinases / metabolism
Treatment Outcome
Tumor Suppressor Proteins / genetics
Tumor Suppressor Proteins / metabolism

Substances

FLCN protein, human
Ointments
Proto-Oncogene Proteins
Tumor Suppressor Proteins
MTOR protein, human
TOR Serine-Threonine Kinases
Sirolimus